Drug Trial Radar · NCT06736327
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Dec 13, 2024
Primary completion
Jul 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety, tolerability, PK profile, immunogenicity, and antitumor activity of SKB500 in subjects with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
SKB500Drug
The administration route of SKB500 is intravenous infusion, with a dosing frequency of Q3W.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the incidence of adverse events (AEs)Time frame: Up to 3 years
- Evaluate the incidence of serious adverse events (SAEs)Time frame: Up to 3 years
- Evaluate the incidence of treatment related adverse events (TRAEs)Time frame: Up to 3 years
- Evaluate the incidence of dose-limiting toxicities (DLTs)Time frame: Day 1 to Day 21 in Cycle 1 in the dose escalation part
Locations
1 site in 1 country. Site status is shown where the registry gives one.
JILIN Cancer Hospital
Jilin City, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.